Joseph R. Martel

Joseph R. Martel

Ophthalmology

11216 Trinity River Dr.
Suite H
Rancho Cordova, CA 95670

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Efficacy and safety of clobetasol propionate ophthalmic nanoemulsion for treating intraocular inflammation and pain associated with cataract surgery: two phase 3 multicentre, randomised, placebo-controlled, double-masked clinical studies.

Efficacy and safety of clobetasol propionate ophthalmic nanoemulsion for treating intraocular inflammation and pain associated with cataract surgery: two phase 3 multicentre, randomised, placebo-controlled, double-masked clinical studies.

Journal: BMJ open

Published: May 27, 2026

A Dose-Selection Study of Clobetasol Propionate Ophthalmic Suspension that Evaluated Inflammation and Pain after Cataract Surgery.

A Dose-Selection Study of Clobetasol Propionate Ophthalmic Suspension that Evaluated Inflammation and Pain after Cataract Surgery.

Journal: Journal of cataract and refractive surgery

Published: July 25, 2025

Dose-selection study of clobetasol propionate ophthalmic suspension that evaluated inflammation and pain after cataract surgery.

Dose-selection study of clobetasol propionate ophthalmic suspension that evaluated inflammation and pain after cataract surgery.

Journal: Journal of cataract and refractive surgery

Published: July 25, 2025

Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.

Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.

Journal: BMC ophthalmology

Published: August 08, 2023

OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study.

OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study.

Journal: Clinical therapeutics

Published: July 16, 2022

Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study.

Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: March 30, 2022

Reply.

Reply.

Journal: Ophthalmology

Published: August 11, 2017

Reply.

Reply.

Journal: Ophthalmology

Published: August 11, 2017

Reply.

Reply.

Journal: Ophthalmology

Published: July 19, 2017

Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.

Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.

Journal: Ophthalmology

Published: September 23, 2016

Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.

Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.

Journal: Eye & contact lens

Published: July 29, 2016

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

Journal: Ophthalmology

Published: May 21, 2015

Showing 1-12 of 19

Last Updated: 09/26/2026